The radiopharmaceutical 225Ac-J591 produced responses in patients with metastatic prostate cancer in a phase 1 study. The radiopharmaceutical 225Ac-J591 produced responses in patients with metastatic prostate cancer in a phase 1 study.
Mayo Adhesive Probability scores can predict overall survival in patients undergoing surgery for T1 renal cell carcinoma, according to researchers. MAP scores can predict overall survival in patients undergoing surgery for T1 RCC, according to researchers.
Erdafitinib produced responses in 94% of patients with intermediate-risk, FGFR3-mutant NMIBC in the phase 2 THOR-2 trial. Erdafitinib produced responses in 94% of patients with intermediate-risk, FGFR3-mutant NMIBC in the phase 2 THOR-2 trial.
Cretostimogene grenadenorepvec can produce durable complete responses in patients with high-risk non-muscle invasive bladder cancer that does not respond to Bacillus Calmette-Guérin therapy, a phase 3 trial suggests. Cretostimogene grenadenorepvec can produce durable complete responses in patients with high-risk NMIBC that does not respond to BCG therapy.
UGN-102 produced a high complete response rate in patients with low-grade, intermediate-risk NMIBC in the phase 3 ENVISION trial. UGN-102 produced a high complete response rate in patients with low-grade, intermediate-risk NMIBC in the phase 3 ENVISION trial.